Clinical Trial Update: High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL [Phase 1]

View source ↗

Summary

This report covers a Phase 1 trial evaluating high-dose simvastatin, an HMG-CoA reductase inhibitor, in relapsed chronic lymphocytic leukemia. The study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: John Haslip | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED